KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Thermo Fisher Scientific (TMO) Research & Development (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Research & Development for 16 consecutive years, with $374.0 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Research & Development rose 14.37% year-over-year to $374.0 million, compared with a TTM value of $1.4 billion through Dec 2024, up 3.96%, and an annual FY2025 reading of $1.4 billion, up 0.5% over the prior year.
  • Research & Development was $374.0 million for Q4 2024 at Thermo Fisher Scientific, up from $346.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $392.0 million in Q4 2021 and bottomed at $245.0 million in Q1 2020.
  • Average Research & Development over 5 years is $339.2 million, with a median of $345.5 million recorded in 2023.
  • The sharpest move saw Research & Development skyrocketed 43.51% in 2020, then dropped 16.37% in 2023.
  • Year by year, Research & Development stood at $376.0 million in 2020, then increased by 4.26% to $392.0 million in 2021, then fell by 0.26% to $391.0 million in 2022, then decreased by 16.37% to $327.0 million in 2023, then grew by 14.37% to $374.0 million in 2024.
  • Business Quant data shows Research & Development for TMO at $374.0 million in Q4 2024, $346.0 million in Q3 2024, and $339.0 million in Q2 2024.